{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:31:31Z","timestamp":1791826291184,"version":"4.3.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,12,16]],"date-time":"2018-12-16T00:00:00Z","timestamp":1544918400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"internal funding"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1093\/jac\/dky508","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T15:08:42Z","timestamp":1542380922000},"page":"1035-1043","source":"Crossref","is-referenced-by-count":33,"title":["<i>SLC22A2<\/i> variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV"],"prefix":"10.1093","volume":"74","author":[{"given":"A","family":"Borghetti","sequence":"first","affiliation":[{"name":"Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-8815","authenticated-orcid":false,"given":"A","family":"Calcagno","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Infectious Diseases, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-9694","authenticated-orcid":false,"given":"J","family":"Cusato","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Infectious Diseases, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Belmonti","sequence":"additional","affiliation":[{"name":"Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"D\u2019Avolio","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Infectious Diseases, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Ciccarelli","sequence":"additional","affiliation":[{"name":"Department of Psychology, Catholic University of Sacred Heart, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"La Monica","sequence":"additional","affiliation":[{"name":"Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Colafigli","sequence":"additional","affiliation":[{"name":"Infectious Dermatology, IFO S. Gallicano, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Delle Donne","sequence":"additional","affiliation":[{"name":"Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"De Marco","sequence":"additional","affiliation":[{"name":"Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Tamburrini","sequence":"additional","affiliation":[{"name":"Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Visconti","sequence":"additional","affiliation":[{"name":"Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Di Perri","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Infectious Diseases, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"De Luca","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Siena University Hospital, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Bonora","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Infectious Diseases, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Di Giambenedetto","sequence":"additional","affiliation":[{"name":"Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,14]]},"reference":[{"key":"key\n\t\t\t\t2019031509373411500_dky508-B1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/QAI.0000000000000849","article-title":"Discontinuation of initial antiretroviral therapy in clinical practice: moving toward individualized therapy","volume":"71","author":"Di Biagio","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B2"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B3"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B4","first-page":"14","article-title":"Dolutegravir neuropsychiatric adverse events: specific drug effect or class effect","volume":"20","author":"Yombi","year":"2018","journal-title":"AIDS Rev"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B5","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1097\/QAD.0b013e32835aa141","article-title":"Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study","volume":"26","author":"Madeddu","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijantimicag.2014.10.013","article-title":"Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from the SCOLTA project long-term surveillance","volume":"45","author":"Madeddu","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B7","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B8","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1097\/QAD.0000000000001279","article-title":"Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice","volume":"30","author":"De Boer","year":"2016","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"Hoffmann","year":"2017","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/QAD.0000000000001459","article-title":"Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe","volume":"31","author":"Menard","year":"2017","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QAD.0000000000001351","article-title":"Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir","volume":"31","author":"Bonfanti","year":"2017","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/QAI.0000000000001269","article-title":"Psychiatric symptoms in patients receiving dolutegravir","volume":"74","author":"Fettiplace","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B13","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/jac\/dkx053","article-title":"Tolerability of integrase inhibitors in a real-life setting","volume":"72","author":"Penafiel","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B14","author":"Hoffmann"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B15","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1186\/s12879-017-2717-x","article-title":"Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1","volume":"17","author":"Yagura","year":"2017","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/1574886313666180116124046","article-title":"Dolutegravir-related neurological adverse events: a case report of successful management with therapeutic drug monitoring","volume":"13","author":"Parant","year":"2018","journal-title":"Curr Drug Saf"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/bcp.12639","article-title":"Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients","volume":"80","author":"Zhang","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neulet.2016.09.025","article-title":"Localization of organic cation transporter 2 (OCT2) in monoaminergic and cholinergic axon terminals of the mouse brain","volume":"633","author":"Matsui","year":"2016","journal-title":"Neurosci Lett"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.neuroscience.2013.08.011","article-title":"Organic cation transporter 2 (SLC22A2), a low-affinity and high-capacity choline transporter, is preferentially enriched on synaptic vesicles in cholinergic neurons","volume":"252","author":"Nakata","year":"2013","journal-title":"Neuroscience"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B20","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/mp.2011.87","article-title":"Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response","volume":"17","author":"Bacq","year":"2012","journal-title":"Mol Psychiatry"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B21","volume-title":"Symptom Checklist-90- R: Administration, Scoring, and Procedures Manual","author":"Derogatis","year":"1994","edition":"3rd edn"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B22","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B23","author":"Sarno","year":"2011"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpba.2017.02.002","article-title":"UPLC-MS\/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma","volume":"138","author":"Simiele","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00008571-200207000-00007","article-title":"Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function","volume":"12","author":"Leabman","year":"2002","journal-title":"Pharmacogenetics"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ng.2982","article-title":"An atlas of genetic influences on human blood metabolites","volume":"46","author":"Shin","year":"2014","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2014.09.008","article-title":"Role of organic cation transporters (OCTs) in the brain","volume":"146","author":"Courousse","year":"2015","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/FPC.0b013e32832cc7e9","article-title":"Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin","volume":"19","author":"Chen","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejca.2017.08.033","article-title":"Potential role of polymorphisms in the transporter genes ENT1 and MATE1\/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer","volume":"86","author":"Suenaga","year":"2017","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B30","doi-asserted-by":"crossref","first-page":"e0136451","DOI":"10.1371\/journal.pone.0136451","article-title":"Substrate-dependent inhibition of the human organic cation transporter OCT2: a comparison of metformin with experimental substrates","volume":"10","author":"Hacker","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B31","volume-title":"The Amygdala: Neurobiological Aspects of Emotion, Memory and Mental Dysfunction","author":"Aggleton","year":"1992"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1124\/jpet.108.146225","article-title":"Transport of lamivudine [(\u2212)-\u03b2-L-2\u2032, 3\u2032-dideoxy-3\u2032-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3","volume":"329","author":"Minuesa","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1124\/jpet.116.238337","article-title":"Tenofovir disoproxil fumarate is not an inhibitor of human organic cation transporter 1","volume":"360","author":"Shen","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B34","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s40264-016-0440-y","article-title":"Neuropsychiatric effects of HIV antiviral medications","volume":"39","author":"Treisman","year":"2016","journal-title":"Drug Saf"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the Phase III VIKING-3 Study","volume":"210","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019031509373411500_dky508-B36","first-page":"177","article-title":"Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus","volume":"73","author":"Castagna","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/4\/1035\/28078074\/dky508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T09:40:09Z","timestamp":1552642809000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/4\/1035\/5248197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,14]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,12,14]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky508","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2018,12,14]]}}}